Vmn2r110 Inhibitors
Vmn2r110 Inhibitors represent a diverse group of chemicals that impede the function of the Vmn2r110 protein through various indirect mechanisms, each specific to the chemical's action on certain cellular pathways. For instance, Quinidine and Tetrodotoxin exploit the common strategy of blocking voltage-gated sodium channels, thus dampening neuronal excitability, which is critical for the function of neurons that express Vmn2r110. In a similar vein, ZD7288 targets HCN channels, leadingto a reduction in pacemaker currents that could affect the excitability of Vmn2r110-expressing neurons. Other inhibitors, such as Suramin and Pertussis toxin, disrupt G-protein-coupled receptor (GPCR) functionality; Suramin by preventing G-protein interactions or downstream signaling, and Pertussis toxin by specifically inhibiting the Gi/o alpha subunits with which Vmn2r110 may interact. Bicuculline's antagonism of GABA_A receptors and CNQX's blockade of AMPA/kainate receptors both serve to alter neurotransmission balance, potentially affecting Vmn2r110 activity if it is integrated within these neural circuits.
Moreover, the inhibitory landscape is further complicated by chemicals like Concanavalin A, which can impede Vmn2r110 function through steric hindrance by binding to glycoproteins essential for protein-protein interactions. Methyllycaconitine and Alpha-Bungarotoxin both target nicotinic acetylcholine receptors (nAChRs), which, when inhibited, could diminish cholinergic modulation of Vmn2r110 signaling. Clozapine's broad interaction with neurotransmitter systems can also lead to indirect inhibition of Vmn2r110 by altering the neurotransmitter balance in the brain. Lastly, Phorbol 12-myristate 13-acetate (PMA) indirectly affects Vmn2r110 by activating PKC, which could phosphorylate and negatively regulate Vmn2r110 or its associated pathways. Each chemical inhibitor, through its distinct interaction with signal transduction pathways or cellular processes, contributes to the multifaceted approach to inhibiting Vmn2r110 activity, though not through direct binding or antagonism of Vmn2r110 itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine blocks voltage-gated sodium channels, which may lead to decreased neuronal excitability. In the context of Vmn2r110, which is a chemosensory receptor, reduced excitability could diminish signal transduction, indirectly inhibiting Vmn2r110 activity. | ||||||
Concanavalin A | 11028-71-0 | sc-203007 sc-203007A sc-203007B | 50 mg 250 mg 1 g | $119.00 $364.00 $947.00 | 17 | |
Concanavalin A is a lectin that can bind to glycoproteins and potentially interfere with protein-protein interactions. If Vmn2r110 relies on such interactions for its function, Concanavalin A could inhibit its activity through steric hindrance. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin is a polysulfonated naphthylurea that can interfere with growth factor signaling and G-protein coupled receptor (GPCR) function. As Vmn2r110 is a GPCR, Suramin could inhibit its signaling by preventing G-protein interaction or downstream signaling. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A sc-200402B sc-200402C | 50 mg 500 mg 5 g 10 g | $69.00 $364.00 $2500.00 $4100.00 | 11 | |
Clozapine is an atypical antipsychotic known to interact with various neurotransmitter systems, including serotonergic, dopaminergic, and muscarinic pathways. This broad spectrum of activity could indirectly affect the neural circuits in which Vmn2r110 is involved. | ||||||
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Bicuculline is a GABA_A receptor antagonist. By inhibiting GABAergic inhibitory neurotransmission, it could alter the balance of excitation and inhibition in the brain, indirectly affecting the activity of Vmn2r110 if it is part of neural circuits controlled by GABAergic signaling. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $208.00 | 2 | |
CNQX is an AMPA/kainate receptor antagonist that prevents excitatory glutamatergic transmission. If Vmn2r110 is expressed in glutamatergic neurons or downstream of such pathways, CNQX could reduce its activity by decreasing excitatory input. | ||||||
α-Bungarotoxin | 11032-79-4 | sc-202897 | 1 mg | $351.00 | 5 | |
Alpha-Bungarotoxin is a competitive antagonist of nAChRs. By blocking acetylcholine binding, it can inhibit cholinergic neurotransmission, which could reduce the modulation of Vmn2r110 activity if Vmn2r110 is influenced by cholinergic signals. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). By activating PKC, PMA can modulate various cellular pathways. If PKC activation leads to phosphorylation events that negatively regulate Vmn2r110, PMA could indirectly inhibit its activity. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
Pertussis toxin is an inhibitor of Gi/o alpha subunits of G-proteins. Since Vmn2r110 is a GPCR, pertussis toxin could inhibit its signaling by preventing G-protein coupling and subsequent downstream signaling events. | ||||||